China approves Eli Lilly’s weight loss drug as country launches obesity awareness campaign

Eli Lil­ly’s tirzepatide has been ap­proved for weight man­age­ment in Chi­na, en­ter­ing what’s ex­pect­ed to be a sub­stan­tial mar­ket for GLP-1s.

Tirzepatide — mar­ket­ed in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.